• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一组吡嗪酸酯类化合物作为抗结核前药的定量构效关系建模。

QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.

机构信息

Department of Pharmacy, University of São Paulo, SP, Brazil.

出版信息

Arch Pharm (Weinheim). 2010 Feb;343(2):91-7. doi: 10.1002/ardp.200900216.

DOI:10.1002/ardp.200900216
PMID:20099263
Abstract

Tuberculosis is an infection caused mainly by Mycobacterium tuberculosis. A first-line antimycobacterial drug is pyrazinamide (PZA), which acts partially as a prodrug activated by a pyrazinamidase releasing the active agent, pyrazinoic acid (POA). As pyrazinoic acid presents some difficulty to cross the mycobacterial cell wall, and also the pyrazinamide-resistant strains do not express the pyrazinamidase, a set of pyrazinoic acid esters have been evaluated as antimycobacterial agents. In this work, a QSAR approach was applied to a set of forty-three pyrazinoates against M. tuberculosis ATCC 27294, using genetic algorithm function and partial least squares regression (WOLF 5.5 program). The independent variables selected were the Balaban index (J), calculated n-octanol/water partition coefficient (ClogP), van-der-Waals surface area, dipole moment, and stretching-energy contribution. The final QSAR model (N = 32, r(2) = 0.68, q(2) = 0.59, LOF = 0.25, and LSE = 0.19) was fully validated employing leave-N-out cross-validation and y-scrambling techniques. The test set (N = 11) presented an external prediction power of 73%. In conclusion, the QSAR model generated can be used as a valuable tool to optimize the activity of future pyrazinoic acid esters in the designing of new antituberculosis agents.

摘要

结核病是一种主要由结核分枝杆菌引起的感染。一线抗分枝杆菌药物是吡嗪酰胺(PZA),它部分作为一种前药被吡嗪酰胺酶激活,释放出活性物质吡嗪酸(POA)。由于吡嗪酸穿过分枝杆菌细胞壁有一定的难度,而且吡嗪酰胺耐药株不表达吡嗪酰胺酶,因此已经评估了一组吡嗪酸酯作为抗分枝杆菌药物。在这项工作中,使用遗传算法函数和偏最小二乘回归(WOLF 5.5 程序),对一组 43 种吡嗪酸酯对结核分枝杆菌 ATCC 27294 的 QSAR 方法进行了应用。所选的自变量是 Balaban 指数(J)、计算的正辛醇/水分配系数(ClogP)、范德华表面积、偶极矩和拉伸能贡献。最终的 QSAR 模型(N = 32,r(2) = 0.68,q(2) = 0.59,LOF = 0.25,LSE = 0.19)通过留一法交叉验证和 y 打乱技术进行了全面验证。测试集(N = 11)具有 73%的外部预测能力。总之,生成的 QSAR 模型可用于优化未来吡嗪酸酯在新型抗结核药物设计中的活性,是一种有价值的工具。

相似文献

1
QSAR modeling of a set of pyrazinoate esters as antituberculosis prodrugs.一组吡嗪酸酯类化合物作为抗结核前药的定量构效关系建模。
Arch Pharm (Weinheim). 2010 Feb;343(2):91-7. doi: 10.1002/ardp.200900216.
2
Lipophilic pyrazinoic acid amide and ester prodrugs stability, activation and activity against M. tuberculosis.亲脂性吡嗪酰胺和酯前药的稳定性、活化作用及对结核分枝杆菌的活性
Eur J Pharm Sci. 2009 Jun 28;37(3-4):257-63. doi: 10.1016/j.ejps.2009.02.012. Epub 2009 Mar 6.
3
Esters of Pyrazinoic Acid Are Active against Pyrazinamide-Resistant Strains of Mycobacterium tuberculosis and Other Naturally Resistant Mycobacteria In Vitro and Ex Vivo within Macrophages.吡嗪酸酯对耐吡嗪酰胺的结核分枝杆菌菌株及其他天然耐药分枝杆菌在体外和巨噬细胞内的体内实验中均具有活性。
Antimicrob Agents Chemother. 2015 Dec;59(12):7693-9. doi: 10.1128/AAC.00936-15. Epub 2015 Oct 5.
4
Quantitative structure-activity relationships for the in vitro antimycobacterial activity of pyrazinoic acid esters.吡嗪酸酯体外抗分枝杆菌活性的定量构效关系
J Med Chem. 1996 Aug 16;39(17):3394-400. doi: 10.1021/jm950538t.
5
Antimycobacterial activity of pyrazinoate prodrugs in replicating and non-replicating Mycobacterium tuberculosis.吡嗪酸前药在增殖期和非增殖期结核分枝杆菌中的抗分枝杆菌活性
Tuberculosis (Edinb). 2016 Jul;99:11-16. doi: 10.1016/j.tube.2016.04.002. Epub 2016 Apr 9.
6
Antimycobacterial activity of a series of pyrazinoic acid esters.一系列吡嗪酸酯的抗分枝杆菌活性
J Med Chem. 1992 Apr 3;35(7):1212-5. doi: 10.1021/jm00085a007.
7
Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis.吡嗪酰胺可抑制结核分枝杆菌的类真核脂肪酸合成酶I(FASI)。
Nat Med. 2000 Sep;6(9):1043-7. doi: 10.1038/79558.
8
Potential tuberculostatic agent: micelle-forming pyrazinamide prodrug.
Arch Pharm (Weinheim). 2006 Jun;339(6):283-90. doi: 10.1002/ardp.200500039.
9
Activity of n-propyl pyrazinoate against pyrazinamide-resistant Mycobacterium tuberculosis: investigations into mechanism of action of and mechanism of resistance to pyrazinamide.正丙基吡嗪酸酯对耐吡嗪酰胺结核分枝杆菌的活性:吡嗪酰胺作用机制及耐药机制的研究
Antimicrob Agents Chemother. 1995 Jun;39(6):1269-71. doi: 10.1128/AAC.39.6.1269.
10
Synthesis, anti-tuberculosis activity, and 3D-QSAR study of 4-(adamantan-1-yl)-2-substituted quinolines.4-(金刚烷-1-基)-2-取代喹啉的合成、抗结核活性及三维定量构效关系研究
Bioorg Med Chem. 2007 Jan 15;15(2):626-40. doi: 10.1016/j.bmc.2006.10.064. Epub 2006 Nov 1.

引用本文的文献

1
Improving ADMET Prediction Accuracy for Candidate Drugs: Factors to Consider in QSPR Modeling Approaches.提高候选药物的 ADMET 预测准确性:QSPR 建模方法中需要考虑的因素。
Curr Top Med Chem. 2024;24(3):222-242. doi: 10.2174/0115680266280005231207105900.
2
High Systemic Exposure of Pyrazinoic Acid Has Limited Antituberculosis Activity in Murine and Rabbit Models of Tuberculosis.吡嗪酸的高全身暴露在结核病小鼠和兔模型中具有有限的抗结核活性。
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4197-205. doi: 10.1128/AAC.03085-15. Print 2016 Jul.
3
Synthesis and evaluation of a pyrazinoic acid prodrug in Mycobacterium tuberculosis.
结核分枝杆菌吡嗪酸前药的合成与评价。
Saudi Pharm J. 2014 Sep;22(4):376-80. doi: 10.1016/j.jsps.2013.12.005. Epub 2013 Dec 25.
4
Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.用于结核病药物发现的计算数据库、途径和化学信息学工具。
Trends Microbiol. 2011 Feb;19(2):65-74. doi: 10.1016/j.tim.2010.10.005. Epub 2010 Dec 2.